A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...
BofA analyst Tim Anderson raised the firm’s price target on Eli Lilly (LLY) to $1,000 from $997 and keeps a Buy rating on the shares after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback